Head-to-head evidence
AZD8630 vs WIN378
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: TSLP · full Asthma pipeline
AZD8630
Developed by AstraZeneca and partners
NCT06529419 · Phase 2 · completed
The study randomized 537 participants across three AZD8630 dose groups and placebo, with participants, care providers, investigators, and outcome assessors quadruple-blinded. Its primary endpoint was a clinical exacerbation-related measure, but the primary comparison cannot yet be judged because results have not been reported.
WIN378
Developed by Windward Bio under a licence from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT05790694 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: July 2027 · NCT07120503 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD8630's landscape · WIN378's landscape